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Abstract
AIM: To provoke persistent/chronic multiorgan inflam-
matory response and to contribute to stones formation 
followed by fibrosis in hepatobiliary and pancreatic tissues. 
METHODS: Tumor necrosis factor receptors 1 and 2 
(TNFR1/R2) deficient mice reared in-house were given 
dibutyltin dichloride (DBTC) twice within 10 d by oral 
gavage delivery. Sham control animals received vehicle 
treatment and naïve animals remained untreated 
throughout the study. Animals were monitored daily for 
symptoms of pain and discomfort. The abdominal and 
hindpaw hypersensitivity were assessed with von Frey 
microfilaments. Exploratory behaviors were recorded at 
the baseline, after initiation of treatment, and before 
study termination. Histopathological changes were 
examined postmortem in tissues. Collagen accumulation 
and fibrosis were confirmed with Sirius Red staining. 
RESULTS: Animals lost weight after oral administration 
of DBTC and developed persistent inflammatory 
abdominal and hindpaw hypersensitivity compared to 
sham-treated controls (P  < 0.0001). These pain related 
secondary mechanical hypersensitivity responses 
increased more than 2-fold in DBTC-treated animals. 
The drastically diminished rearing and grooming rates 
persisted after DBTC administration throughout the 
study. Gross as well as micropathology at one month 
confirmed that animals treated with DBTC developed 
chronic hepatobiliary injuries evidenced with activation 
of stellate cells, multifocal necrosis, fatty degeneration 
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ORIGINAL ARTICLE
Multiorgan chronic inflammatory hepatobiliary pancreatic 
murine model deficient in tumor necrosis factor receptors 
1 and 2
Basic Study
Helieh S Oz
of hepatocytes, periportal infiltration of inflammatory 
cells, and prominent biliary ductal dilation. The 
severity of hepatitis was scored 3.7 ± 0.2 (severe) in 
DBTC-treated animals vs  score 0 (normal) in sham-
treated animals. Fibrotic thickening was extensive 
around portal ducts, in hepatic parenchyma as well 
as in lobular pancreatic structures and confirmed with 
Sirius Red histopathology. In addition, pancreatic 
microarchitecture was presented with distortion of 
islets, and parenchyma, infiltration of inflammatory 
cells, degeneration, vacuolization, and necrosis of 
acinar cells and distention of pancreatic ducts. Extent 
of pancreatic damage and pancreatitis were scored 
3.6 ± 0.4 (severe) for DBTC-treated in contrast to 
score 0 (normal) in sham-treated animals. The gall 
bladder became expanded with ductal distention, 
and occasional bile stones were detected along with 
microscopic hepatic lesions. DBTC-treated animals 
developed splenic hypertrophy with increased weight 
and length (P  < 0.01) along with thymic atrophy 
(P  < 0.001). Finally, colitic lesions and colitis were 
prominent in DBTC-treated animals and scored 3.4 ± 0.3 
(moderately severe) vs  0 (normal) for the sham-treated 
animals. 
CONCLUSION: This is the first report of chronic inflam-
matory multiorgan hepatobiliary pancreatitis, along with 
fibrosis and calculi formation induced reliably utilizing 
oral DBTC administration in TNFR1/R2 deficient mice. 
Key words: Inflammatory pain; Multiorgan; Hepatitis; 
Pancreatitis; Calculi formation; Gall bladder; Hepatobiliary 
inflammation
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Currently there is no reliable model for chronic 
multiorgan inflammatory and fibrosis. Tumor necrosis 
factor (TNF)α initiates inflammation through TNFR1/
R2. TNFR1/R2 deficient mice administered orally with 
dibutyltin dichloride (DBTC) developed significant 
persistent inflammatory and pain related secondary 
mechanical hypersensitivity. DBTC-animals showed 
severe chronic hepatobiliary injuries and prominent 
biliary ductal dilation. Extensive fibrotic thickening 
was evidenced around portal ducts, in hepatic and 
pancreatic structures. DBTC-animals had severe 
pancreatic damage and pancreatitis, hepatic lesions 
with expansion of gall bladder, bile stones and severe 
colitis. This is the first report of chronic inflammatory 
multiorgan hepatobiliary pancreatitis, fibrosis and 
calculi formation in TNFR1/R2 deficient mice. 
Oz HS. Multiorgan chronic inflammatory hepatobiliary pancreatic 
murine model deficient in tumor necrosis factor receptors 1 and 2. 
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INTRODUCTION
Fibrogenesis is a required process in wound healing, 
but persistent inflammatory and fibrotic reaction can 
lead to devastating symptoms and eventually organ 
failure[1,2]. Multiorgan fibrosis is typically the end product 
of various unresolved or repetitive tissue injuries from 
chronic inflammation, infection, radiation exposure, and 
abnormal repair outcome. Loss of function contributes 
to progression of morbidity and mortality. Multiorgan 
fibrosis is a common complication in cystic fibrosis[3], 
systemic sclerosis[4] and primary sclerosing cholangitis[5]. 
Chronic pancreatitis, initiated by idiopathic or recurrent 
inflammation, is manifested with irreversible destruction 
of exocrine parenchyma and pancreatic fibrosis. It is a 
potentially fatal progressive disease leading to diabetes 
mellitus and pancreatic cancer. Pancreatitis is associated 
with spontaneous visceral pain as a chief symptom in 
patients. Neural innervation of the pancreas is pivotal 
in the instigation and continuation of inflammation and 
pain response. Cellular destruction leads to activation 
of pancreatic sensory neurons causing release of 
neurotransmitters in the spinal cord and neurogenic 
signaling then back to the pancreas provoking plasma 
extravasation and neutrophil infiltration[6]. 
Multifactoral gallstones are one of the most pre­
valent gastrointestinal complications with serious 
outcomes such as gallstone pancreatitis and cancer. 
Gallstone disease is a chronic recurrent hepatobiliary 
complication which is characterized by formation of 
gallstones in the hepatic and bile duct, or gallbladder. 
It is manifested by impaired metabolism of cholesterol, 
bilirubin and bile acids[7]. 
Tumor necrosis factor α (TNFα) a proinflammatory 
cytokine, up­regulates various cytokines/chemokines 
to initiate acute and chronic stages of inflammation. 
The biological action of TNFα is chiefly through two 
gene family receptors, TNFR1 and TNFR2. TNFα is 
released mainly by activated macrophages, in addition 
to astroglia, microglia, CD4+ lymphocytes, Natural 
killer cells (NK), and neurons[8­10]. The complete­length 
membrane­crossing TNFα (mTNFα) is sliced by the 
inducible TNF converting enzyme (TACE) to release 
soluble TNFα (sTNFα) and diffusible peptide[11]. TNFα 
release is associated with inflammatory response and 
pain related sensation in patients with pancreatitis, 
hepatitis and inflammatory bowel disease (IBD), as well 
as neuropathy[12]. TNFα contributes to development of 
neuropathic pain[13]. Soluble TNFR1 and R2 neutralize 
circulating TNFα to alleviate pain related responses 
to mechanical allodynia, thermal hyperalgesia or 
peripheral nerve injuries[14­16]. TNFα plays an important 
function in the pathogenesis of acute pancreatitis. 
Recent investigations have demonstrated that TNFα 
inhibition drastically ameliorates the duration of 
experimental acute pancreatitis[17]. TNFα receptor 1 
(TNFR1) gene deletion and etanercept application 
likewise ameliorated the duration of acute pancreatitis 
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in animal models, suggesting potential of etanercept 
and anti­TNFα monoclonal antibodies as therapy 
in clinical pancreatitis[17]. Although, current clinical 
treatments with these biological agents may diminish 
inflammation and pain by reducing TNFα and other 
cytokines, the inflammatory response and pain is 
likely to re­emerge in most patients with autoimmune 
disease including arthritis and IBD[10]. In addition, anti-
TNFα monoclonal antibodies therapy has potential side 
effects such as provoking infections with JC virus, fungi 
and tuberculosis. Currently there is no cure or reliable 
mouse model for chronic pancreatitis.
Previously we have demonstrated that the base­
line mechanical and thermal response to noxious 
stimulation is similar in TNFR1/R2 deficient mice 
vs wildtype background mice. However, TNFR1/R2 
deficient mice develop more severe responses when 
similarly treated with various insults[10,16]. Animal 
models of acute and chronic pancreatitis have been 
utilized to examine mechanisms of pathogenesis, and 
to test possible therapeutic interventions. One of the 
most commonly used pancreatitis models is created by 
serial intraperitoneal administration of concentrations 
of caerulein, an ortholog of cholecystokinin[17]. Other 
chemically induced models have utilized di­n­butyltin 
dichloride (DBTC). DBTC is a polyvinyl carbonate (PVC) 
plastic stabilizer/catalyzer additive, insecticide and 
biocide in agriculture, and antifouling agent in the 
paint and fabric industry that often contaminates food 
and water[18]. Tail vein slow injection of DBTC induces 
relatively unpredictable pancreatitis flares in rats[6]. 
However, DBTC injection is tedious and minor leakage 
results in tail necrosis, gangrene and animal loss. We 
hypothesized that oral administration of DBTC would 
provoke persistent and chronic pancreatitis in animals 
deficient in TNF­receptors. Similarly, TNFR1/R2 may 
accelerate inflammatory response in multiorgans and 
contribute to stones formation and fibrosis in hepato-
biliary and pancreatic tissues. Here we report a chronic 
persistent DBTC-induced inflammatory model by oral 
gavage in TNFR1/R2 deficient mice persisting at least 
one month allowing more clinically relevant studies in 
this model. Pain related behaviors accompanying this 
model are characterized. 
MATERIALS AND METHODS
Animals
All animal procedures were approved by the University 
of Kentucky Institution Animal Care and Use Committee 
(IACUC). Mice were monitored daily for continued 
weight gain/loss and general health. Health status 
and procedures were documented daily on the UK 
IACUC Standard Operating Procedure (SOP-102) 
Post-Operative Evaluation form. Experiments were 
performed using dually deficient TNFR1/R2 mice 
(Jackson Laboratory) on a B6129SF2/J background 
inbred at the University of Kentucky animal facilities 
and provided by Dr. Westlund. Mice were housed in 
individual cages with a 10 h/14 h dark/light reversed 
cycle to accommodate behavioral test during their 
active dark period. Mice were allowed free access 
to food and water ad libitum, except 2 h before and 
during behavioral testing. 
Induction of persistent chronic pancreatitis 
Chronic persistent pancreatitis was induced in mice 
utilizing DBTC (Dibutyltin dichloride, Sigma-Aldrich, 
St Louis, MO). DBTC (10 mg/kg) was dissolved in 
95% ethanol (two parts) and then mixed with glycerol 
(three parts) and given orally. Mice received DBTC 
by oral gavage (200 μL volume). Intragastric gavage 
administration was performed by Dr. Oz, an expert 
veterinarian scientist, in conscious animals, using 
appropriate bended gavage needles (22 gauge, 1 inch 
length, 1.25 mm ball diameter). Sham control mice 
were given the vehicle (95% ethanol + glycerol, 2:3) 
alone and Naïve control animals remained untreated. 
Animals were monitored until fully active. In order 
to induce chronic inflammation, mice received a 2nd 
treatment by oral gavage within 10 d. Following induc­
tion of pancreatitis the animals were monitored daily 
for activity, appearance, and signs of abdominal dis­
comfort. They were weighed regularly and tested for 
hypersensitivity on the hindpaw plantar foot pad and 
the shaved abdominal surface. After completion of the 
final behavioral testing, one month after induction, 
the animals were euthanatized with isoflurane over­
exposure, the thorax opened, blood samples collected 
by cardiac puncture, and tissue samples collected for 
histological evaluation.
Assessment of secondary mechanical allodynia by 
testing hindpaw withdrawal threshold 
Pain­related behavior was assessed throughout the 
study by the determining secondary mechanical 
threshold to assess hyperalgesia/allodynia. The von 
Frey test is a standard comparison used in the field of 
pain research. Day 0, baseline testing to determine 
footpad nociceptive responses was performed testing 
hindpaw withdrawal latency to mechanical stimuli 
with von Frey fibers. Reflex testing for secondary 
mechanical hyperalgesia/allodynia with von Frey 
fibers was developed by Max von Frey, who in 1896 
identified “pain spots” on human skin. Mechanical 
nociceptive thresholds were analyzed as described 
previously[10,19]. Paw withdrawal response latencies 
were assessed weekly throughout the study. Mice 
were placed into clear cylindrical plastic enclosures (7 
cm × 4 cm × 4 cm) on a smooth metal meshed (3 
mm × 3 mm) platform (36 cm × 29 cm × 21.5 cm). 
Mechanical withdrawal threshold testing was done on 
the plantar surface of both hindpaws using a set of 
8 von Frey monofilaments [(4.74) 6.0 g; (4.31) 2.0 
g; (4.08) 1.0 g; (3.61) 0.4 g; (3.22) 0.16 g; (2.83) 
0.07 g; (2.36) 0.02 g; (1.65) 0.008 g]. The von Frey 
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against the floor, and abdomen retractions or arching 
the back. Recordings were masked and analyzed by the 
investigator.
Necropsy and sample collection 
Tissue collection: At the end of the one month ex-
periment, animals were deeply anesthetized with 
isoflurane inhalation. Pancreatic, hepatic, gall bladder 
tissues were excised and a portion was fixed in cold 4% 
paraformaldehyde in 0.1 mol/L phosphate buffer saline 
(PBS). Thymus and splenic tissues were removed, 
weighed, and fixed in paraformaldehyde. Colonic 
tissues were removed and flushed with cold PBS, and 
portion of ascending and descending colon were fixed 
for histopathological examinations. 
Histopathology
Hepatic and pancreatic samples were collected and 
immerse fixed overnight in 4% paraformaldehyde 
in 0.1 mol/L PBS, then transferred into 70% ethanol 
and embedded in paraffin. Sections were cut (5 μm), 
rehydrated, stained with hematoxylin and eosin for 
histopathological changes. In order to detect collagen 
fiber deposits, sections were further stained with Sirius 
Red (Electron Microscopy Sciences, #26357­02), using 
routine histological protocols[20]. 
Pancreatitis scores
Pancreatic tissues and a portion of the small intestine 
along with spleen were removed and processed for 
histopathological evaluations of the pancreatitis. The 
severity of lesions was scored on a 0­4 grade on the 
basis of the histopathological changes as follows: 0 - 
normal pancreatic microstructure, no inflammatory 
mononuclear cell infiltration; 1 ­ slight inflammatory 
mononuclear cell infiltration, with no detectable 
parenchymal destruction; 2 ­ mild pancreatitis, edema, 
focal parenchymal destruction with mononuclear cell 
infiltration; 3 ­ moderate pancreatitis, with diffuse 
parenchyma destruction, presence of necrosis, and 
reduced number of islets; and 4 ­ severe pancreatitis, 
parenchyma mostly destroyed and replaced with 
adipose tissues, loss of pancreatic islets, presence of 
fibrosis and or calculi. 
Hepatitis score 
A portion of the right lobe from liver tissues of each 
mouse was placed in an embedding cassette and 
fixed in paraformaldehyde as mentioned above. 
The specimens were dehydrated and embedded in 
paraffin, and tissue sections of 5 μm were stained 
with Hematoxylin Eosin. Each slide was evaluated 
under Ziess light microscopy. Hepatic lesions were 
graded on a scale of 0 to 4+ based on degeneration, 
inflammation, and necrosis as follow: Grade 0 - 
no detectable lesions, degeneration, infiltration of 
inflammatory cells, normal tissue appearance; Grade 1 
- focal infiltration of inflammatory cells in the tissue and 
filaments were applied perpendicularly to the plantar 
surface with sufficient force to bend the monofilament 
slightly and held for about 5 s, and 5 to 10 times 
with 15 s intervals. A positive response was defined 
as an abrupt withdrawal (flick response) of the foot 
during stimulation or immediately after the removal of 
stimulus. Whenever there was a negative or positive 
response, the next stronger or weaker filament was 
applied, respectively. Testing proceeded in this manner 
until four fibers had been applied after the first one 
caused a withdrawal response, allowing the estimation 
of the mechanical withdrawal threshold.
Pain-related behavioral evaluations for abdomen: 
Prior to induction of inflammation with DBTC admi-
nistration, baseline testing of abdominal nociceptive 
responses to mechanical stimuli was performed with 
von Frey fibers applied to the upper left abdominal 
quadrant skin of mice as previously described[10,19]. 
Mechanical hypersensitivity in the abdominal area was 
quantified by measuring the number of withdrawal 
events (either abdominal withdraw from the von Frey 
filament or consequent licking of the abdominal area, 
or whole body withdrawal) in response to normally 
innocuous or sub­threshold mechanical stimuli. Testing 
continued weekly throughout the study.
Evaluation of the pain-related posture: The ab­
normal posture of each animal with an affected hindlimb 
was given a single score using a subjective pain­related 
behavioral scale (spontaneous pain rating score 0­5) 
i.e. 0­ normal; 1­ curling of the toes, 2­ aversion of the 
paw; 3­ partial weight bearing; 4­ non­weight bearing 
and guarding; and 5­ avoidance of any contact with the 
hindlimb. 
Pain-related gait disturbance: Gait disturbances 
(curling toes, limping, guarding, rearing and grooming 
were tallied by an observer blinded to treatment group 
as in our previous studies[10]. 
Spontaneous visceral pain assessment: The 
animals were placed individually in the observation 
chamber for a 25 min recording session. The obser­
vation chamber is a 28 cm × 17.5 cm × 12.5 cm see­
through plastic home cage with one mirrored side 
located in an isolated room with constant “white noise”. 
A digital camera located 0.5 meter from the chamber 
with an unobstructed view was used to record animals 
spontaneous visceral pain related behaviors. The 
camera was linked to a computer recording program 
for offline data analysis (Logitech Image Studio). The 
chamber was washed with a detergent disinfectant 
and dried after each use between animals. Postures 
defined as statistically significant increase in visceral 
pain­related behavior in this study included rearing, 
grooming and licking of the lower abdomen, stretching 
the abdomen or hindlimb, lowering the abdomen 
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hepatocytes degeneration; Grade 2 ­ mild multifocal 
infiltration of inflammatory cells, and hepatocytes 
degeneration; Grade 3 - moderate multifocal infiltration 
of inflammatory cells and hepatocytes degeneration; 
and Grade 4 - severe diffuse infiltration of inflammatory 
cells, necrosis, or fibrosis. 
Colitis evaluation scores
Colonic tissues were flushed with PBS (pH 7.2) and a 
portion from proximal and distal colonic tissues were 
fixed for histological examinations. The fixed sections 
were processed and stained with Hematoxylin Eosin 
and slides evaluated by Ziess light microscopy. The 
severity of colitis was assessed with a histological 
semi­quantitative grading score. The scores were 
based on histopathological features with a numeric 
value (0: normal to 4: severe) assigned according to 
the tissue involvement corresponding to the following 
criteria[21,22]. Grade 0: No detectable lesions, no 
inflammatory cells, and normal mucosal appearance; 
Grade 1: Focal inflammatory infiltrate in the mucosa; 
Grade 2: Mild multifocal inflammation with moderate 
expansion into the mucosa; Grade 3: Moderate multi-
focal inflammation with moderate expansion of the 
mucosa; and Grade 4: Severe diffuse inflammation 
with crypt epithelium disruption and ulceration.
Statistical analysis
All results are expressed as mean and standard error 
of mean (± SEM) unless otherwise stated. Data were 
analyzed using paired t­test comparison of groups for 
histology or analysis of variance (ANOVA) followed by 
Bonferroni post hoc comparison using GraphPad Prism 
Software for behavioral testing over time (San Diego, 
CA, United States). Statistical significance was set at p 
≤ 0.05. 
RESULTS
Body weight loss 
No major differences in body weight, behavioral 
analysis was detected between sham­treated and 
naïve control animals. Additionally, sham­treated and 
naïve control animals and wildtypes did not develop 
any histopathological lesions. Therefore, only sham­
treated controls are reported here. Oral administration 
of DBTC resulted in weight lost as early as 3 d after 
treatment which persisted throughout the study, and 
animals developed persistent inflammatory abdominal 
and hindpaw hypersensitivity as compared to sham­
treated animals. DBTC application induced significant 
body weight loss (p < 0.001) in compression to 
weight gain in sham­treated control animals. The 
major weight loss occurred during the 1st wk of DBTC 
inoculation when animals lost about 10% of their body 
weight, compared to weight gain in sham­treated 
animals. The body weight afterward became stable 
in DBTC-treated mice until the end of the one month 
study, but remained less than the sham­treated group 
(Figure 1). 
Behavioral pain related modifications
DBTC-treated animals had significant reduction in 
physical activities such as, cage crossing, rearing 
and grooming activity (p < 0.0001) compared to 
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Figure 1  Percent weight gain in sham-treated controls (Sham) vs weight 
loss in dibutyltin dichloride-treated animals. n = 8 animals/group (P < 0.001). 
DBTC: Dibutyltin dichloride.
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Figure 2  Rearing and grooming rate changes and hindpaw mechanical 
threshold modification due to dibutyltin dichloride-treatments. A: Rearing 
and grooming rates significantly diminished in dibutyltin dichloride (DBTC)-
treated animals vs the sham-administered animals and persisted throughout the 
study (P < 0.0001); B: Hindpaw withdrawal threshold response to mechanical 
stimuli in DBTC-treated animals (DBTC) had significant decreased vs sham-
administered control (sham) mice (P < 0.0001). n = 5 animals/group.
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naïve sham­treated ones presumably attributed 
to the abdominal discomfort (Figure 2A). Hindpaw 
mechanical threshold was significantly decreased 
in DBTC-treated animals (p < 0.0001) tested using 
von Frey microfilaments (Figure 2B). In addition, 
responses to 3 different von Frey fibers with increasing 
grams force applied to the abdominal skin indicated 
DBTC-treated animals had significantly decreased 
mechanical threshold compared to sham­treated 
control (respectively p < 0.0001 from force 2.3 g, 2.8 
g, p < 0.001 to force 3.22 g) (Figure 3). In contrast 
sham­treated animals demonstrated a partial visceral 
response to the higher filaments with forces of 3.22 g 
and above. 
Splenomegaly and thymic degeneration
DBTC animals developed splenic hypertrophy with 
significant increase in weight and length of the 
spleens (p < 0.01). Splenic histopathologic studies 
demonstrated loss of medulla, irregular formation of 
trabecules, with captured trace of blirubin and bile 
deposits. In contrast, thymic tissues from DBTC-
treated animals showed central degeneration and 
atrophy. The thymus was atrophied, and thymic weight 
significantly decreased in DBTC-treated animals (p < 
0.001) compared to sham­treated animals (Figure 4). 
Pancreatitis
Sham­treated animals demonstrated normal pan­
creatic structures with prominent islets (Figure 5A). 
In contrast, DBTC-treated animals developed gross 
as well as micropathology confirming the moderate to 
severe chronic pancreatitis. Pancreatic parenchyma 
presented with edema, congestion, distortion of 
microarchitecture, and infiltration of inflammatory 
cells. Pancreatic and acinar cells showed degeneration, 
fatty necrosis, and fibrosis. The pancreatic ducts 
became prominent and distended in DBTC-treated 
animals. These findings were consistent with fibrotic 
thickening which were particularly prominent in the 
vicinity of the primary duct, as well in surrounding 
lobular pancreatic parenchyma as confirmed with 
Sirius Red histopathological studies.
Also noted was loss of microstructure indicated by 
the presence of irregular and degenerated islets, along 
with vacuolization and necrosis of β cells accompanied 
by invasion of inflammatory cells. The sizes as well as 
the numbers of the pancreatic islets were significantly 
diminished in DBTC-treated compared with the sham-
treated animals (Figure 5B). A few small and shrunken 
islets were scattered throughout the pancreatic 
parenchyma, but overall loss of β cells was evident. 
In addition, pancreatic ducts had become thickened 
and expanded containing traces of debris and calculi 
formation (Figure 6A). Extent of pancreatic damage 
scored (0­ normal to 4 most severe) were 3.6 ± 0.4 
(severe) in DBTC-treated in contrast to score 0 (normal) 
for sham­treated animals.
Gall bladder 
Gall bladder showed extensive expansion with ductal dis-
tension and occasional detected bile stones (Figure 6B). 
Hepatitis 
Hepatic tissues became enlarged, friable and pale or 
yellowish in color with a spotted appearance indicating 
moderately severe hepatitis. Macroscopic hepatic 
injuries were evidenced with activation of stellate 
cells, degeneration of hepatocytes, and multifocal 
and central necrosis (Figure 7A). Additionally, hepatic 
structure showed fatty degeneration of hepatocytes, 
and periportal infiltration of inflammatory cells, 
along with presence of visible ductal dilation. Fibrotic 
thickening was prominent in the vicinity of portal 
ducts, and surrounding lobular hepatic parenchyma 
as confirmed with Sirius Red histopathological studies. 
The severity of hepatitis was scored 3.7 ± 0.2 (severe) 
in DBTC-treated animals compared to the score 0 
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Figure 3  Abdominal threshold sensitivity to mechanical stimuli was 
determined with different gram forces of von Frey microfilaments as 
demonstrated here to 2.3 g (P < 0.001), 2.8 g (P < 0.0001), 3.2 g (P < 0.001), 
in dibutyltin dichloride-treated vs sham-treated controls (sham). Data is 
presented as the 50% mechanical threshold response. n = 5 animals/group.
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Figure 4  Splenic weight as well as splenic length (not shown) signi-
ficantly increased in dibutyltin dichloride-treated animals (P < 0.01). In 
contrast thymic weight decreased in dibutyltin dichloride-treated (DBTC) vs 
the sham-treated (sham) animals (P < 0.001) due to atrophy and depletion of 
lymphocytes and thymocytes. n = 8 animals/group.
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(normal) in sham­treated animals.
Colitis 
Colonic tissue showed extensive necrosis and loss of 
intestinal epithelial cells, distortion of cryptic structures, 
thickening of mucosa due to invasion of inflammatory 
cells, and some cryptic microabscess formation, 
presenting advanced colitis (Figure 7B). Colonic lesions 
and colitis in DBTC-treated animals were scored 3.4 ± 
0.3 (moderately severe) compared to 0 (normal) for 
Figure 5  Pancreatic photomicrographs from sham-treated normal control (A) compared to dibutyltin dichloride-treated animal (B). A: Pancreas: 
Photomicrograph demonstrates sham-treated control pancreas with normal pancreatic microstructure and islet cells. Representative slide from n = 8 animals/group; 
B: Pancreatitis: Photomicrograph illustrates pancreas from a dibutyltin dichloride-treated animal with significant loss of pancreatic structure and islets, acinar atrophy, 
infiltration of inflammatory cells, fatty deposits and edema (magnification × 40). Representative slide from n = 8 animals/group.
A B
Figure 6  Photomicrograph from pancreatic ductal calculi formation (A), as well as hepatic and gall bladder gross pathological structure (B) in dibutyltin 
dichloride-treated animals. A: Calculi formation: Photomicrograph illustrates histopathologic structure from a representative pancreas of a dibutyltin dichloride-treated 
animal to demonstrate ductal distension and calculi formation. Representative slide from n = 8 animals/group (magnification × 40); B: Photograph illustrates hepatic 
gross lesions (red arrows), expanded bile duct (blue arrows) and gall bladder (white arrow) from DBTC-treated animal. Representative from n = 8 animals/group. 
A B
Figure 7  Photomicrograph of hepatitis (A) and colitis (B) from dibutyltin dichloride-treated animals. A: Hepatitis: Photomicrograph illustrates necrosis of 
hepatocytes, infiltration of inflammatory cells (magnification × 40). Representative slide from n = 8 animals/group; B: Colitis: Photomicrograph demonstrates distortion 
of colonic microstructure, loss of brush boarder epithelial cells, infiltration of inflammatory cells into mucosa and cryptic abscess formation. Representative slide from n 
= 8 animals/group.
A B
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the sham­treated animals. 
DISCUSSION 
Here our findings may provide a new model to 
better approach investigation of chronic multiorgan 
inflammatory and visceral pain in murine model and 
to study possible potential targets in this model for the 
treatment of chronic hepatobiliary and pancreatitis. 
Acute pancreatitis is manifested by histopatholo­
gical transformations, including the presence of in­
flammatory mediators, acinar atrophy, fat necrosis, 
intraductal hemorrhage, and stromal proliferation[23]. 
Chronic pancreatitis is distinguished by recurrent or 
continuous inflammation of pancreatic progressive 
atrophy and irreversible fibrosis, with demise of 
exocrine and endocrine malfunction in severe forms. 
While, severe and uninhibited abdominal pain is the 
main aspect of persistent pancreatitis, the mechanism/
s by which the pain is induced is poorly explored 
possibly due to a lack of available appropriate animal 
model to mimic chronic pancreatitis[24]. In current 
study the TNFR1/R2 deficient animals displayed 
significant pain related modifications such as decreases 
in mechanical threshold after DBTC treatment that 
persisted through the one month experiment until 
the end of the study. The significant decreases in 
mechanical threshold were detected on foot pads and 
abdomen after the induction of the injury as compared 
with sham treated animals.
Although, chronic pancreatitis in human is dis­
tinguished by irreversible fibrosis, yet pancreatic 
fibrosis in animal models are mainly reversible[25]. 
Indeed persistent fibrosis in vital organs results in 
significant morbidity and mortality worldwide. While, 
organ fibrogenesis is typically the end product of 
various non­resolving or repetitive injuries such as 
chronic infection and radiation exposure; abnormal 
repair reaction followed by tissue injuries to contri­
bute to the progression of organ fibrosis. Indeed, 
fibrogenesis is required in natural wound healing 
process, persistent fibrogenesis in organs can lead 
to devastating symptoms and organ failure[1,2]. At 
the cellular level fibrogenesis is remarkably similar 
progress in different organs and can cause generalized 
fibrosis in these tissues. Yet, currently there is no 
appropriate model available to study systemic fibrosis. 
Similarly chronic hepatitis and hepatic fibrosis result 
from excess extracellular matrix produced primarily by 
hepatic stellate cells. We and other investigators have 
shown that proinflammatory cytokines (e.g., TNFα) 
and other inflammatory mediators such as growth 
factors are regulated by matrix metalloproteinase 
(MMPs) expressions[20,26]. Further activation of Stellate 
cells is major event in hepatic fibrosis formation 
caused by multiple injuries due to chemicals, infectious 
agents, surgical and/or inflammatory cytokine and 
chemokines which prompt proliferation and transfor­
mation of stellate cells to secret extra cellular matrix. 
Additionally, the mesenchyme­specific transcription 
factor forkhead box f1 (Foxf1) in liver is specifically 
expressed in hepatic stellate cells. Recently, a lipid 
based liver-specific delivery system also called “dbtc” 
is reported to be efficient to transfer the Foxf1 siRNA 
to activated hepatic stellate cells and silence genes 
expressed in different cell types in liver when used in 
an acute mouse model of bile duct ligation­induced 
secondary cholestasis[27]. 
Pancreatitis models are divided into surgically 
induced and chemical administration induced hyper­
secretion of the pancreatic enzymes. The surgical 
models include ligation and/or cannulation of the 
biliopancreatic ducts with infusion of variety of so­
lutions, or the formation of closed duodenal loops. 
Pancreatic fibrosis in bile duct ligated rats is a difficult 
model to induce and requires increased stimulation. 
Chemical secretagogues (caerulein or l­arginine) 
include administration of DBTC to cause a partial 
blockage of the pancreatic ducts to induce pancreatic 
disease through enzymic reflux into the gland[28]. 
Various environmental chemicals have been 
implicated in the induction of autoimmune responses. 
Di­n­dibutyltin dichloride is an organotin compound 
and PVC plastic additive that frequently released to 
contaminate food and water. As eventually DBTC is 
degraded in the environment with possible harmful 
effects on man and animals[29]. Some therapeutic 
indications of DBTC include at a dose of 10 mg/kg 
per day for 5 consecutive days effective to eliminate 
Trypanosoma brucei infection in mice[23]. LD50 of DBTC 
is reported to be 90 mg/kg[30]. Metabolism of DBTC 
by cytochrome P450 enzymes plays an important 
role in the induction of biological effects, as DBTC 
with affinity for mitochondria depresses respiration 
and elevates serum enzymatic activities resulting in 
hepatic injuries[31]. Thymus atrophy noted in the current 
investigation was similar to that reported as a con­
sequence rather than a cause in DBTC-intraperitoneal 
injected rats[32]. Increased proliferin expression and 
promotion of morphological thymic transformation 
reportedly occurring at similar concentrations most 
probably are DBTC-induced thymus involution. Indeed, 
this reaction is due to antiproliferative activity of DBTC, 
as observed by inhibition of thymidine incorporation of 
thymocytes isolated from DBTC-treated rats[32]. After 
administration of 4­61 mg/kg iv or 120­240 mg/kg 
oral DBTC, a dose dependent reversible reduction 
of thymus weight and number of thymocytes were 
observed in mice. Iv administration of DBTC highly 
increased the level of total bilirubin in serum of 
these animals. But, the level of bilirubin in serum did 
not correlate with the thymotoxic effects of DBTC 
in mice[33]. Of interest, toxicity of DBTC in mice is 
reported after 3 consecutive daily high doses of 50 
mg/kg, killing 75% and the survivors developed 
severe hepatic and bile duct damage. While 3 daily 
doses of 20 mg/kg caused only mild bile duct and 
liver lesions[34].
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In another study, mice were given DBTC at 8, 15, 
or 30 mg/kg per day by gavage on days 0­3 or days 4­7 
and sacrificed on day 18 of pregnancy. The incidence 
of embryonic loss increased on days 0­3 at 15 mg or 
over and, on days 4­7 with 8 mg/kg bw/d and higher. 
However, no increase in the rate of fetus malformations 
was observed after the DBTC administration. A decline 
in the serum progesterone levels was noted in dams 
given DBTC at 30 mg/kg per day, which might have 
affected the pregnancy initiation, maintenance, and 
loss when administered during early pregnancy[35]. 
Non­alcoholic steatohepatitis (NASH), the most 
common hepatic disorder, is manifested with inflam­
mation, hepatocyte injury, cell death, fibrosis and 
multiorganelle failure, leading to cirrhosis[26]. Previously 
we reported cytokine/chemokine, extracellular matrix 
accumulation and metalloproteinase upregulation 
in a dietary deficient NASH model[20]. RT­PCR mea­
surements showed a significant overexpression of 
inflammatory cytokines [TNFα, transforming growth 
factor (TGF­β), interleukin (IL-1β), IL-6], suppressor 
of cytokines signaling1 and genes involved in tissue 
remodeling and fibrosis (MMPs, collagen­α1) in the 
hepatic tissues of rats fed methionine-choline deficient 
diet[20].
Furthermore, using DBTC tail injection rat model we 
have shown implication of the endothelin cascade gene 
expression as a major contributing factor in pancreatic 
pain in both pancreatitis and potential pancreatic 
cancer[6]. In the present study oral inoculation of 
DBTC in TNFR1/R2 deficient mice induced a chronic 
persistent multiorgan hepatobiliary pancreatitis as 
confirmed by pathological studies including biliary 
dilation, loss of hepatic and pancreatic architecture 
and islets, edema in parenchyma, infiltration of 
inflammatory cells, degeneration, vacuolization and 
fibrosis, and pancreatic necrosis of acinar cells. Pain 
related behaviors were increased in animals with 
pancreatic inflammation including visceral pain­
related behavior and secondary cutaneous mechanical 
hypersensitivity which increased greater than 2­fold. 
Here lack of TNF receptors appears to accelerate 
the inflammatory response in multiple organs and 
contribute to fibrosis in hepatobiliary and pancreatic 
tissues. A serum proteome profiling analysis in our 
previous study in TNFR1/R2 deficient mice with 
pain related behaviors in an arthritis model revealed 
high levels of serum inflammatory factors. The 
inflammatory factors included TNFα, which is regulated 
by the activation of normally T-cell expressed and 
secreted (RANTES), chemokine (C­X­C motif) ligand 
9 [CXCL9 (MIG)], chemokine (C-X-C motif) ligand 10 
[CXCL10 (IP-10)], and chemokine (C-C motif) ligand 2 
[CCL2 (MCP­1)][10].
Primary sclerosing cholangitis is a complex hepatic 
disorder, characterized by chronic inflammation of the 
biliary epithelium, and cholestasis resulting in multifocal 
bile duct strictures, fibrosis of hepatic parenchyma 
and biliary tract leading to cirrhosis and malignancy. 
The etiology of primary sclerosing cholangitis is not 
fully discovered and no effective therapy is available[5]. 
Gallstone, one of the most prevalent gastrointestinal 
complications, is multifactoral, with serious outcomes 
such as acute gallstone pancreatitis and gallbladder 
cancer. Gallstone disease is a chronic recurrent 
hepatobiliary complication which is manifested by 
creation of gallstones in the hepatic and bile duct, 
or gallbladder. It is manifested by dysfunctional 
metabolism of cholesterol, bilirubin and bile acids[7]. 
Other factors may involve genetic, environmental 
and steroids. The prevalence of gallstone disease has 
increased because of sedentary lifestyle and poor 
diets. Gallstones are known as a common cause of 
pancreatitis. From 932 patients with acute pancreatitis 
40% had gallstones, and 22% alcohol induced[36]. 
Further, pancreatitis is frequent amongst IBD patients. 
Gallstones are reported as the most frequent cause 
of pancreatitis in IBD patients which cause growing 
diagnostic challenges[37]. Thus, this model may fa­
cilitate study of fibrogenesis and/or fibrosis resolution 
in multiple vital organs leading to development of 
novel technologies and therapeutic strategies aimed at 
lessening organ fibrosis. 
In conclusions, this is the first report of a chronic 
inflammatory multiorgan hepatobiliary pancreatitis 
along with fibrosis and calculi formation model 
that can be induced reliably with use of oral DBTC 
administration in TNFR1/R2 deficient mice. Future 
studies will utilize this model in investigations of anti­
fibrotic and analgesic therapeutics. 
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Background
Chronic multiorgan, pancreatitis and hepatobiliary complications manifested 
with irreversible fibrosis and spontaneous visceral pain in patients. Currently 
there is no cure or reliable model available for chronic pancreatitis or multiorgan 
fibrosis other than repeated dosing with chemical caerulein to produce acute 
flares. An appropriate murine model to mimic the syndrome is desirable. 
Pancreatic fibrosis in bile duct ligated rats is a difficult model to induce and 
requires other increased stimulations. The prevalence of gallstone disease has 
increased because of sedentary lifestyle and poor diets. Dibutyltin dichloride 
(DBTC) is a biocide, and antifouling agent in the paint and fabric industry. Tail 
vein injection of DBTC induces unpredictable pancreatitis flares in rats, DBTC 
injection is tedious, and minor leakage results in tail gangrene and animal loss. 
TNFα proinflammatory cytokine initiates inflammation through its 2 receptors, 
TNFR1/R2. We devised a new chronic model of pancreatitis and multiorgan 
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inflammation in TNFR1/R2 deficient mice using oral DBTC. 
Research frontiers
Currently, there is no cure or reliable model available for chronic pancreatitis 
and multiorgan fibrosis in mice. Persistent pancreatitis manifests with severe 
abdominal pain, but the mechanism/s by which induced is/are poorly explored 
possibly due to lack of appropriate models. Three daily doses of 20 mg/kg 
DBTC caused only mild bile duct and liver lesions, while 3 consecutive 
daily doses of 50 mg/kg DBTC were toxic and killed 75% of mice. TNFα 
proinflammatory cytokine initiates inflammation through its 2 receptors, TNFR1/
R2. Proteome profiling analysis in our previous study in TNFR1/R2 deficient 
mice with persistent pain related behaviors in an arthritis model revealed high 
levels of serum inflammatory cytokines likely responsible for the multiorgan 
inflammatory response in this model.
Innovations and breakthroughs
This is the first report of a chronic inflammatory hepatobiliary pancreatitis, 
colitis and stone formation model that can be induced reliably with use of oral 
DBTC-administration in TNFR1/R2 deficient mice. These findings provide 
this new murine model to better approach investigation of chronic multiorgan 
inflammatory and visceral pain in murine mode. In addition, to facilitate study 
of fibrogenesis and/or fibrosis resolution in multiple vital organs leading 
to development of novel technologies and therapeutic strategies aimed at 
lessening organ fibrosis. 
Applications
This chronic inflammatory hepatobiliary pancreatitis, colitis/fibrosis and stone 
formation model can be induced reliably utilizing oral DBTC in TNFR1/R2 
deficient mice. The model can be used to investigate chronic multiorgan 
inflammatory and visceral pain in mice to explore the mechanisms of injury 
and to study of fibrogenesis and/or fibrosis resolution in multiple vital organs 
leading to development of novel technologies and therapeutic strategies aimed 
at lessening organ fibrosis. This study grants ability for further investigation 
into the use of this model to explore mechanisms of multiorgan injury, the 
biochemical players and the therapeutic exploration for devastating chronic 
multiorgn inflammatory and fibrogenesis such as cystic fibrosis and systemic 
sclerosis as well as cholangitis. 
Terminology
TNFR1/R2 deficient mice are transgenic animals lacking tumor necrosis factor 
receptor 1 and 2 with constant higher proinflammatory TNFα levels compared 
to wildtype background animals. Multiorgan damage, when 2 or more organs 
involved in the course of injury. Fibrogenesis is a process usually followed 
chronic inflammatory to form fibrous structures in and around tissues. Pain 
related mechanical hypersensitivity, is measured by von Frey microfilament 
(an accepted standard procedure), demonstrating decreased tolerance to 
a simple touch manifested with withdraw to protect against induced excess 
pressure while normal animals tolerate the mechanical touch with no withdrawal 
response to the fine microfilament touch. 
Peer-review
This is an interesting and well-written paper. The author provided that TNFR1/
R2 deficient mice treated with DBTC reveal the severe chronic injury of various 
internal organs which was proved with usage of histological methods.
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